Repurposing Chlorpromazine for Anti-Leukemic Therapy with the Drug-in-Cyclodextrin-in-Liposome Nanocarrier Platform.

Investigators demonstrated that drug-in-cyclodextrin-in-liposome (DCL)-based chlorpromazine formulations maintain anti-leukaemic activity, avoid central nervous system accumulation, and allow drug availability adjustments based on the included cyclodextrin.